A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

NCT06340581 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study no longer required.

Conditions

Healthy

Interventions

DRUG: Treatment A: BGF MDI HFA
DRUG: Treatment B: BGF MDI HFO
DRUG: Treatment C: BGF MDI HFO
DEVICE: AeroChamber Plus Flow-Vu Spacer

Sponsor

AstraZeneca

Collaborators

[object Object]